Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study

Mizumoto,Yuki; Yokoyama,Shozo; Matsuda,Kenji; Iwamoto,Hiromitsu; Mitani,Yasuyuki; Tamura,Koichi; Nakamura,Yuki; Murakami,Daisuke; Oka,Masami; Kobayashi,Yasuhito; Yamaue,Hiroki

doi:10.3892/mco.2019.1961

February-2020 Volume 12 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2020 Volume 12 Issue 2

Full Size Image

Article Open Access

Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study

Authors:
- Yuki Mizumoto
- Shozo Yokoyama
- Kenji Matsuda
- Hiromitsu Iwamoto
- Yasuyuki Mitani
- Koichi Tamura
- Yuki Nakamura
- Daisuke Murakami
- Masami Oka
- Yasuhito Kobayashi
- Hiroki Yamaue
View Affiliations / Copyright

Affiliations: Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama 641‑8510, Japan, Department of Surgery, National Hospital Organization Minami Wakayama Medical Center, Wakayama 646‑8558, Japan, Department of Surgery, Wakayama Rosai Hospital, Wakayama 640‑8505, Japan

Copyright: © Mizumoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 126-133
|
Published online on: December 6, 2019

https://doi.org/10.3892/mco.2019.1961
Expand metrics +

Abstract

Adjuvant chemotherapy with capecitabine is frequently not completed due to adverse events, including hand‑foot syndrome. A higher completion rate of capecitabine by reduction of the side effects may improve disease‑free survival and quality of life of affected patients. In the present study, colorectal cancer (CRC) patients were treated with capecitabine (2,500 mg/m2/day), which was taken for five days, followed by an interval of two days (5‑days‑on/2‑days‑off schedule). One course lasted three weeks, and eight courses (24 weeks) were administered. The median number of treatment courses was significantly higher in patients in the 5‑days‑on/2‑days‑off regimen group compared with that of patients in the retrospectively included conventional regimen group (P=0.0438). The frequency of completion of the scheduled treatment by patients in the 5‑days‑on/2‑days‑off regimen group was significantly higher (P=0.0389). The present phase II study suggests that toxicities associated with the 5‑days‑on/2‑days‑off regimen are lower compared with those of the conventional regimen, and that the occurrence of adverse events was higher, but less high‑grade toxicities were reported. The time to treatment failure was also favorable in the new regimen and it demonstrated good feasibility. In conclusion, the present study demonstrated good feasibility with retained quality of life and acceptable adverse effects (mostly low‑grade), and the 5‑days‑on/2‑days‑off regimen should be further evaluated in future randomized controlled trials. The present study was registered in the University Hospital Medical Information Network (UMIN) clinical trial registry (no. UMIN000012813).

View Figures

View References

1	Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002.PubMed/NCBI View Article : Google Scholar
2	Reddy GK: Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in Dukes C colon cancer: Results from the X-ACT trial. Clin Colorectal Cancer. 4:87–88. 2004.PubMed/NCBI View Article : Google Scholar
3	Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, et al: Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial. Br J Cancer. 94:1122–1129. 2006.PubMed/NCBI View Article : Google Scholar
4	Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F and Cassidy J: Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 23:1190–1197. 2012.PubMed/NCBI View Article : Google Scholar
5	Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005.PubMed/NCBI View Article : Google Scholar
6	Twelves CJ: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: Overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 6:278–287. 2006.PubMed/NCBI View Article : Google Scholar
7	Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, et al: Initial report of KSCC0803: Feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients. Int J Clin Oncol. 18:254–259. 2013.PubMed/NCBI View Article : Google Scholar
8	Pentheroudakis G, Pappas P, Golfinopoulos V, Fountzilas G, Nikolaidou M, Boumba VA, Vougiouklakis T, Nikiforidis L, Tzamakou E, Siarabi O, et al: Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol. 60:733–739. 2007.PubMed/NCBI View Article : Google Scholar
9	Sobin LH, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 7th Edition. Wiley-Blackwell, Chichester. 2009.
10	Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 22:3408–3419. 2004.PubMed/NCBI View Article : Google Scholar
11	Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012.PubMed/NCBI View Article : Google Scholar
12	National Cancer Institute (NCI): Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
13	Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB and de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365–376. 1993.PubMed/NCBI View Article : Google Scholar
14	Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, Noguchi Y, Ogasawara H and Yoshida K: A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30. Eur J Cancer. 34:810–815. 1998.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles